Oncology: Personalised, precision care

The institute has come out with breakthrough technologies to beat cancer

Prof. Nir Peled heads Shaare Zedek Medical Center's Integrated Oncology Institute, which offers services to oncology patients at all stages, from diagnosis to formulating treatment programs of chemotherapy, hormonal and biological therapy, to supportive therapy and relief of symptoms and side effects, to pain treatment and supportive treatment for patients in advanced stages. The institute is in a period of very active growth and is positioned to become among Israel's most active cancer programmes with the opening of the first phase of the Cancer Care Center, currently under construction.

A key thought leader in the field of precision care cancer treatment, specifically thoracic oncology, Prof. Peled is a board member of the International Association of Lung Cancer, the former chair of its Screening and Early Detection Committee, and until recently, also served as chair of the Thoracic Cancer Assembly of the European Thoracic Society. He has specialised in some of the world's leading cancer care hospitals, including as a Fulbright postdoctoral fellow at the University of Colorado Cancer Center.

Prof. Peled has published over 250 peer-reviewed articles on topics such as the early diagnosis of lung cancer, biomarker development, and treatment of advanced disease. He is on the editorial board of prestigious medical and science publications, including the Journal of Thoracic Oncology.

Having led and participated in scores of groundbreaking clinical studies, Prof. Peled spearheads state-of-the-art oncological research, including molecular profiling and immunology - the last word in cancer treatment today. In his decades of work, and with the emergence of practical applications for the innovative technologies, he's seen a significant increase in the life expectancy of oncology patients, specifically those with lung cancer.

The experienced, professional team at the Oncology Institute, which includes experts in all fields of oncology, radiation and palliative care, employs novel technologies and devices, while simultaneously integrating the insight gained from Prof. Peled's clinical trials. His current research involves implanting the patient's own tumour tissue in mice that were specially developed for this purpose.

"We provide comprehensive and personalised care for each and every one of our oncology patients," says Prof. Peled. "My colleagues and I work with the belief that it is essential to achieve a good match between the cancer profile and the patient's individual needs. Being aware of the different options gives our patients better control over their own disease, as they endeavour to pave their path for this tough journey."

• Supplements